This brand name is authorized in Cyprus
The drug SADERON contains one active pharmaceutical ingredient (API):
|
1
Letrozole
UNII 7LKK855W8I - LETROZOLE
|
|
Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the aromatase cytochrome P450, resulting in a reduction of oestrogen biosynthesis in all tissues where present. |
Below package inserts are available for further reading:
| Title | Information Source | Document Type | |
|---|---|---|---|
| SADERON Film-coated tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| L02BG04 | Letrozole | L Antineoplastic and immunomodulating agents → L02 Endocrine therapy → L02B Hormone antagonists and related agents → L02BG Aromatase inhibitors |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
